Teva Pharmaceuticals competitors and similar companiesClear all

Teva Pharmaceuticals's competitors and similar companies include Viatris, WuXi AppTec, Merck, Novartis, Pfizer, AstraZeneca, Roche, Sanofi and Allergan.
Teva Pharmaceuticals
Teva Pharmaceuticals
Teva Pharmaceuticals is a global pharmaceutical company.
Viatris
Viatris
Viatris is a pharmaceuticals company.
WuXi AppTec
WuXi AppTec
WuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies.
Merck
Merck
Merck & Co (also known as Merck Sharp & Dohme) is a healthcare manufacturer and distributor of pharmaceuticals.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
AstraZeneca
AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Roche
Roche
Roche Holding is the holding company of F. Hoffmann-La Roche, a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Allergan
Allergan
Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products.
Founding Date
Founding Date
1901
Founding Date
2020
Founding Date
2000
Founding Date
1891
Founding Date
1996
Founding Date
1849
Founding Date
1999
Founding Date
1896
Founding Date
2004
Founding Date
1948
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Petah Tikva, IL HQ
Villa Adelina, AR
Macquarie Park, AU
Minsk, BY
Antwerpen, BE
Sao Paulo, BR
Dupnica, BG
see more
Locations
Canonsburg, US HQ
Carole Park, AU
Millers Point, AU
Sofia, BG
Toronto, CA
Beijing, CN
Beijing, CN
see more
Locations
Shanghai, CN HQ
Beijing, CN
Changzhou, CN
Chengdu, CN
Guangzhou, CN
Nan Tong, CN
Shanghai, CN
see more
Locations
Kenilworth, US HQ
Hydra, DZ
Munro, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
Manama, BH
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Bentley, AU
Footscray, AU
Mulgrave, AU
Sydney, AU
see more
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Dhaka, BD
see more
Locations
Paris, FR HQ
Hydra, DZ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
see more
Locations
Dublin, IE HQ
Buenos Aires, AR
Gordon, AU
Wien, AT
Machelen, BE
Guarulhos, BR
Sao Paulo, BR
see more
Employees
Employees
37,100
Employees
37,00018% decrease
Employees
39,7167% increase
Employees
67,0008% decrease
Employees
104,3231% decrease
Employees
79,0001% increase
Employees
76,1008% increase
Employees
100,9201% decrease
Employees
95,4424% decrease
Employees
17,4003% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
10.3 b
Valuation ($)
29.1 b
Valuation ($)
219.5 b
Valuation ($)
N/A
Valuation ($)
245.6 b
Valuation ($)
169.3 b
Valuation ($)
N/A
Valuation ($)
95.4 b
Valuation ($)
N/A
Twitter followers
Twitter followers
3.6 k
Twitter followers
6.9 k
Twitter followers
4.9 k
Twitter followers
225.1 k
Twitter followers
303 k
Twitter followers
31.8 k
Twitter followers
302.5 k
Twitter followers
245.6 k
Twitter followers
149.9 k
Twitter followers
4
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
19
Number of tweets (last 30 days)
46
Number of tweets (last 30 days)
39
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
4
Number of tweets (last 30 days)
26
Number of tweets (last 30 days)
122
Number of tweets (last 30 days)
23
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
16.8
Average likes per tweet (last 30 days)
2.5
Average likes per tweet (last 30 days)
14.3
Average likes per tweet (last 30 days)
29.4
Average likes per tweet (last 30 days)
7.8
Average likes per tweet (last 30 days)
26.4
Average likes per tweet (last 30 days)
7.6
Average likes per tweet (last 30 days)
18.3
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
97.83%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
46.67%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
74.59%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
346397
Alexa Website Rank
326644
Alexa Website Rank
202234
Alexa Website Rank
121320
Alexa Website Rank
125724
Alexa Website Rank
24521
Alexa Website Rank
44623
Alexa Website Rank
34054
Alexa Website Rank
127348
Alexa Website Rank
413628
Employee Rating
Employee Rating
3.6
Employee Rating
3.5
Employee Rating
2.7
Employee Rating
4.1
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
3.9
Employee Rating
3.8

Financial

Revenue (est.)
Revenue (est.)
$15.9b (FY, 2021)
Revenue (est.)
$17.9b (FY, 2021)
Revenue (est.)
¥22.8b (FY, 2021)
Revenue (est.)
$48.7b (FY, 2021)
Revenue (est.)
$52.9b (FY, 2021)
Revenue (est.)
$81.3b (FY, 2021)
Revenue (est.)
$37.4b (FY, 2021)
Revenue (est.)
CHF62.8b (FY, 2021)
Revenue (est.)
€37.8b (FY, 2021)
Revenue (est.)
$16.1b (FY, 2019)
Cost of goods
Cost of goods
$7b (FY, 2021)
Cost of goods
$12.3b (FY, 2021)
Cost of goods
¥14.6b (FY, 2021)
Cost of goods
$13.6b (FY, 2021)
Cost of goods
$9.7b (FY, 2021)
Cost of goods
$30.8b (FY, 2021)
Cost of goods
$5.9b (FY, 2021)
Cost of goods
(CHF15.5b) (FY, 2021)
Cost of goods
(€10.7b) (FY, 2021)
Cost of goods
$2.5b (FY, 2019)
Gross profit
Gross profit
$9b (FY, 2021)
Gross profit
$5.6b (FY, 2021)
Gross profit
¥8.3b (FY, 2021)
Gross profit
$35.1b (FY, 2021)
Gross profit
$45.1b (FY, 2021)
Gross profit
$50.5b (FY, 2021)
Gross profit
$32b (FY, 2021)
Gross profit
CHF50.4b (FY, 2021)
Gross profit
€28.9b (FY, 2021)
Gross profit
$13.6b (FY, 2019)
Net income
Net income
$447m (FY, 2021)
Net income
($1.3b) (FY, 2021)
Net income
¥5.1b (FY, 2021)
Net income
$13b (FY, 2021)
Net income
$24b (FY, 2021)
Net income
$22b (FY, 2021)
Net income
$115m (FY, 2021)
Net income
CHF14.9b (FY, 2021)
Net income
€6.2b (FY, 2021)
Net income
($5.1b) (FY, 2019)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
125 (FY, 2021)
Countries
100 (FY, 2020)
Countries
N/A
Countries
N/A
Countries
100 (Q1, 2020)
Facilities
Facilities
90 (FY, 2019)
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
21 (FY, 2019)
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
15 (Dec, 2020)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
13 (FY, 2019)
Manufacturing Sites
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
39 (FY, 2021)
Manufacturing Sites
N/A
Manufacturing Sites
23 (FY, 2019)
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Patients Included in Clinical Trials
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
33 k (FY, 2017)
Patients Included in Clinical Trials
235.2 k (FY, 2020)
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
36 (Jan, 2022)
Phase I Trials Products (Oncology)
9 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
37 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
25 (FY, 2021)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
11 (Jan, 2022)
Phase II Trials Products (Oncology)
12 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
24 (FY, 2020)
Phase III Trials Products
54 (FY, 2021)
Phase III Trials Products
27 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Neuroscience)
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
5 (Jan, 2022)
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
1 (FY, 2019)
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
27 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
27 (Jan, 2022)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
171 (FY, 2020)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
91 (FY, 2019)
Projects in R&D Pipeline
N/A
Registration Phase Products
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
8 (FY, 2021)
Registration Phase Products
10 (FY, 2021)
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
6 (FY, 2017)
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
4 (FY, 2020)
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A

Funding

Total funding raised
Total funding raised
$ 358m
Total funding raised
N/A
Total funding raised
$ 902.6m
Total funding raised
$ 5.6m
Total funding raised
$ 6.5m
Total funding raised
N/A
Total funding raised
$ 1b
Total funding raised
$ 7.8b
Total funding raised
$ 310m
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Viatris
HQ
Canonsburg, US
Employees
37,000↓ 18% decrease

Viatris is a pharmaceuticals company.

View company
WuXi AppTec
HQ
Shanghai, CN
Employees
39,716↑ 7% increase

WuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies.

View company
Merck
HQ
Kenilworth, US
Employees
67,000↓ 8% decrease

Merck & Co (also known as Merck Sharp & Dohme) is a healthcare manufacturer and distributor of pharmaceuticals.

View company
Novartis
HQ
Basel, CH
Employees
104,323↓ 1% decrease

Novartis is a company that researches, develops, manufactures, and markets healthcare products.

View company